Estimated abundances of cetacean species in the Northeast Atlantic from Norwegian shipboard surveys conducted in 2014-2018

A ship-based mosaic survey of Northeast Atlantic cetaceans was conducted over a 5-year period between 2014–2018. The area surveyed extends from the North Sea in the south (southern boundary at 53oN), to the ice edge of the Barents Sea and the Greenland Sea. Survey vessels were equipped with 2 independent observer platforms that detected whales in passing mode and applied tracking procedures for the target species, common minke whales (Balaenoptera acutorostrata acutorostrata). Here we present abundance estimates for all non-target species for which there were sufficient sightings. We estimate the abundance of fin whales (Balaenoptera physalus) to be 11,387 (CV=0.17, 95% CI: 8,072–16,063), of humpback whales (Megaptera novaeangliae) to be 10,708 (CV=0.38, 95% CI: 4,906–23,370), of sperm whales (Physeter macrocephalus) to be 5,704 (CV=0.26, 95% CI: 3,374–9,643), of killer whales (Orcinus orca) to be 15,056 (CV=0.29, 95% CI: 8,423–26,914), of harbour porpoises (Phocoena phocoena) to be 255,929 (CV=0.20, 95% CI: 172,742–379,175), dolphins of genus Lagenorhynchus to be 192,767 (CV=0.25, 95% CI: 114,033–325,863), and finally of northern bottlenose whales (Hyperoodon ampullatus) to be 7,800 (CV=0.28, 95% CI: 4,373–13,913). Additionally, our survey effort in the Norwegian Sea in 2015 contributed to the 6th North Atlantic Sightings Survey (NASS) and the survey was extended into the waters north and east of Iceland around Jan Mayen island. This NASS extension, along with our Norwegian Sea survey in 2015, was used to estimate the abundance of fin whales, humpback whales, and sperm whales. All estimates presented used mark-recapture distance sampling techniques and were thus corrected for perception bias. Our estimates do not account for additional variance due to distributional shifts between years or biases due to availability or responsive movement.publishedVersio

Estimated abundances of cetacean species in the Northeast Atlantic from two multiyear surveys conducted by Norwegian vessels between 2002-2013

Two shipboard line-transect surveys of the Northeast Atlantic were conducted between 2002–2007 and 2008–2013 to meet the ongoing requirements of the Revised Management Procedure (RMP) for common minke whales (Balaenoptera acutorostrata acutorostrata) developed by the International Whaling Commission’s Scientific Committee. Here we present estimated abundances for non-target species for which there were sufficient sightings, including fin whales (Balaenoptera physalus), humpback whales (Megaptera novaeangliae), sperm whales (Physeter macrocephalus), killer whales (Orcinus orca), harbour porpoises (Phocoena phocoena), and dolphins of genus Lagenorhynchus. The 2 surveys were conducted using a multiyear mosaic survey design with 2 independent observer platforms operating in passing mode, each with 2 observers. The abundances of Lagenorhynchus spp. from the 2002–2007 survey were estimated using single-platform standard distance sampling methods because of uncertainty in identifying duplicate sightings. All other estimates were derived using mark-recapture distance sampling techniques applied to a combined-platform dataset of observations, correcting for perception bias. Most notably, we find that the abundance of humpback whales, similar in both survey periods, has doubled since the 1990s with the most striking changes occurring in the Barents Sea. We also show that the pattern in distribution and abundance of fin whales and sperm whales is consistent with our earlier surveys, and that abundances of small odontocete species, which were not estimated in earlier surveys, show stable distributions with some variation in their estimates. Our estimates do not account for distributional shifts between years or correct for biases due to availability or responsive movement.publishedVersio

Panel-based Assessment of Ecosystem Condition of Norwegian Barents Sea Shelf Ecosystems - Appendices

publishedVersio

Panel-based Assessment of Ecosystem Condition of Norwegian Barents Sea Shelf Ecosystems - Appendices

Source at https://hi.no/hi

Panel-based Assessment of Ecosystem Condition of Norwegian Barents Sea Shelf Ecosystems

The System for Assessment of Ecological Condition, coordinated by the Norwegian Environment Agency, is intended to form the foundation for evidence-based assessments of the ecological condition of Norwegian terrestrial and marine ecosystems not covered by the EU Water Framework Directive. The reference condition is defined as “intact ecosystems”, i.e., a condition that is largely unimpacted by modern industrial anthropogenic activities. An ecosystem in good ecological condition is defined as a system that does not deviate substantially from this reference condition in structure, functions or productivity. This means that, in practice, what is assessed here is the extent to which an ecosystem is impacted by anthropogenic drivers. This report describes the first operational assessment of the ecological condition of Norwegian Arctic and Sub-Arctic marine shelf ecosystems in the Barents Sea. The assessment method employed is the Panel-based Assessment of Ecosystem Condition (PAEC1), and the current assessment has considered to what extent the Barents Sea shelf ecosystems deviate from the reference condition2 by evaluating change trajectories

Panel-based Assessment of Ecosystem Condition of Norwegian Barents Sea Shelf Ecosystems

The System for Assessment of Ecological Condition, coordinated by the Norwegian Environment Agency, is intended to form the foundation for evidence-based assessments of the ecological condition of Norwegian terrestrial and marine ecosystems not covered by the EU Water Framework Directive. The reference condition is defined as “intact ecosystems”, i.e., a condition that is largely unimpacted by modern industrial anthropogenic activities. An ecosystem in good ecological condition is defined as a system that does not deviate substantially from this reference condition in structure, functions or productivity. This means that, in practice, what is assessed here is the extent to which an ecosystem is impacted by anthropogenic drivers. This report describes the first operational assessment of the ecological condition of Norwegian Arctic and Sub-Arctic marine shelf ecosystems in the Barents Sea. The assessment method employed is the Panel-based Assessment of Ecosystem Condition (PAEC1), and the current assessment has considered to what extent the Barents Sea shelf ecosystems deviate from the reference condition2 by evaluating change trajectories.Panel-based Assessment of Ecosystem Condition of Norwegian Barents Sea Shelf EcosystemspublishedVersio

Status for miljøet i norske havområder - Rapport fra Overvåkingsgruppen 2023

I denne rapporten gir Overvåkingsgruppen, for første gang, en felles vurdering av miljøtilstanden i Barentshavet og havområdene utenfor Lofoten, Norskehavet og Nordsjøen med Skagerrak. Det er også første rapport som bruker resultater fra det nylig utviklede fagsystemet for vurdering av økologisk tilstand. I denne rapporten dekkes to hovedtemaer: (1) Dominerende trekk i status og utvikling i økosystemet i alle tre havområdene, basert på vurderingene av økologisk tilstand, Overvåkingsgruppens rapport om forurensning fra 2022, indikatorer fra Overvåkingsgruppen som ikke er dekket under vurdering av økologisk tilstand, samt rapporter og annen relevant informasjon fra forskning, og (2) en vurdering av karbonbinding i marint plankton, marine vegetasjonstyper og marine sedimenter. I tillegg er det gitt en oppsummering for endringer i ytre påvirkning, vurdering av kunnskapsbehov samt en vurdering av indikatorverdier i forhold til referanseverdier og tiltaksgrenser. Vurderingen av dominerende trekk i utvikling og tilstand av miljøet som er gitt i kapittel 2, utgjør Overvåkingsgruppens bidrag til Faglig forums samlerapport om det faglige grunnlaget for revisjon og oppdatering av de helhetlige forvaltningsplanene for norske havområder.Status for miljøet i norske havområder - Rapport fra Overvåkingsgruppen 2023publishedVersio

Test Performance Characteristics of the AIR, GAD-7 and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease

Rationale: Anxiety is a common comorbidity of chronic obstructive pulmonary disease (COPD) that is associated with higher morbidity and mortality. We evaluated three anxiety screening questionnaires: the Generalized Anxiety Disorder 7-Item Scale (GAD-7), the Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A), and the Anxiety Inventory for Respiratory Disease (AIR).Objectives: To evaluate and compare the test performance characteristics of three anxiety screening questionnaires, using the Mini-International Neuropsychiatric Interview (MINI), version 7.0, as the "gold standard."Methods: Individuals with COPD were recruited at 16 centers. The MINI and questionnaires were administered by trained research coordinators at an in-person visit and readministered by telephone 2-4 weeks later. A composite score for the presence of any Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) anxiety disorder was computed, based on the MINI as the gold standard, compared with a participant screening positive on self-report measures for these analyses.Results: Two hundred and twenty eligible individuals with COPD were enrolled; 219 completed the study. Eleven percent were identified as having a DSM-V anxiety disorder, based on the MINI. Elevated anxiety symptoms based on questionnaires were 38% for the AIR, 30% for the GAD-7, and 20% for the HADS-A. Area under the receiver operating characteristic curve (AUC) was highest for the GAD-7 (0.78; 95% confidence interval [CI], 0.69-0.87), followed by the HADS-A (0.74; 95% CI, 0.64-0.84) and the AIR (0.66; 95% CI, 0.56-0.76). The AUC for the GAD-7 was significantly greater than for the AIR (P = 0.014). Sensitivity was not statistically different among the questionnaires: 77% for the GAD-7, 63% for the HADS-A, and 66% for the AIR. The HADS-A had the highest specificity, 85%, which was significantly higher than that of the GAD-7 (77%; P < 0.001) and the AIR (65%; P < 0.001); GAD-7 specificity was higher than AIR specificity (P < 0.001).Conclusions: Symptoms of anxiety among patients with COPD as identified by screening questionnaires were common and significantly higher than the prevalence of anxiety disorder meeting DSM-V criteria. The GAD-7, the HADS-A and the AIR questionnaires had fair to moderate psychometric properties as screening tools for anxiety in individuals with COPD, indicating the need for improved measures for this patient population

Expression quantitative trait locus fine mapping of the 17q12–21 asthma locus in African American children: a genetic association and gene expression study

Background: African ancestry is associated with a higher prevalence and greater severity of asthma than European ancestries, yet genetic studies of the most common locus associated with childhood-onset asthma, 17q12–21, in African Americans have been inconclusive. The aim of this study was to leverage both the phenotyping of the Children's Respiratory and Environmental Workgroup (CREW) birth cohort consortium, and the reduced linkage disequilibrium in African Americans, to fine map the 17q12–21 locus. Methods: We first did a genetic association study and meta-analysis using 17q12–21 tag single-nucleotide polymorphisms (SNPs) for childhood-onset asthma in 1613 European American and 870 African American children from the CREW consortium. Nine tag SNPs were selected based on linkage disequilibrium patterns at 17q12–21 and their association with asthma, considering the effect allele under an additive model (0, 1, or 2 effect alleles). Results were meta-analysed with publicly available summary data from the EVE consortium (on 4303 European American and 3034 African American individuals) for seven of the nine SNPs of interest. Subsequently, we tested for expression quantitative trait loci (eQTLs) among the SNPs associated with childhood-onset asthma and the expression of 17q12–21 genes in resting peripheral blood mononuclear cells (PBMCs) from 85 African American CREW children and in upper airway epithelial cells from 246 African American CREW children; and in lower airway epithelial cells from 44 European American and 72 African American adults from a case-control study of asthma genetic risk in Chicago (IL, USA). Findings: 17q12–21 SNPs were broadly associated with asthma in European Americans. Only two SNPs (rs2305480 in gasdermin-B [GSDMB] and rs8076131 in ORMDL sphingolipid biosynthesis regulator 3 [ORMDL3]) were associated with asthma in African Americans, at a Bonferroni-corrected threshold of p<0·0055 (for rs2305480_G, odds ratio [OR] 1·36 [95% CI 1·12–1·65], p=0·0014; and for rs8076131_A, OR 1·37 [1·13–1·67], p=0·0010). In upper airway epithelial cells from African American children, genotype at rs2305480 was the most significant eQTL for GSDMB (eQTL effect size [β] 1·35 [95% CI 1·25–1·46], p<0·0001), and to a lesser extent showed an eQTL effect for post-GPI attachment to proteins phospholipase 3 (β 1·15 [1·08–1·22], p<0·0001). No SNPs were eQTLs for ORMDL3. By contrast, in PBMCs, the five core SNPs were associated only with expression of GSDMB and ORMDL3. Genotype at rs12936231 (in zona pellucida binding protein 2) showed the strongest associations across both genes (for GSDMB, eQTLβ 1·24 [1·15–1·32], p<0·0001; and for ORMDL3 (β 1·19 [1·12–1·24], p<0·0001). The eQTL effects of rs2305480 on GSDMB expression were replicated in lower airway cells from African American adults (β 1·29 [1·15–1·44], p<0·0001). Interpretation: Our study suggests that SNPs regulating GSDMB expression in airway epithelial cells have a major role in childhood-onset asthma, whereas SNPs regulating the expression levels of 17q12–21 genes in resting blood cells are not central to asthma risk. Our genetic and gene expression data in African Americans and European Americans indicated GSDMB to be the leading candidate gene at this important asthma locus.6 month embargo; published: 01 May 2020This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee